UNSPSC 51172835: Paraformaldehyde/titanium dioxide/zinc oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172835 Paraformaldehyde/titanium dioxide/zinc oxide is a Commodity code covering chemical compounds and mineral oxides used in pharmaceutical and industrial applications. State and local procurement activity under this code centers on generic multi-source pharmaceutical and over-the-counter product supply agreements, where paraformaldehyde, titanium dioxide, and zinc oxide function as active or inactive pharmaceutical ingredients in formulations distributed through government healthcare and institutional facilities. Issuing bodies include multistate cooperative purchasing alliances administering centralized pharmaceutical procurement on behalf of participating state health departments, local government facilities, and participating state and local agencies across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Proposals were due March 26, 2026. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements. All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The RFP weights price competitiveness at 75 percent and evaluates fixed pricing, administrative fee compliance, EDI capability, and pricing flexibility through flat price, net price formats, or WAC-minus structures. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with contract terms of two years for new responders and optional extensions at MMCAP's discretion.